Literature DB >> 812927

Host-parasite relationships in experimental airborne tuberculosis. V. Lack of hematogenous dissemination of Mycobacterium tuberculosis to the lungs in animals vaccinated with Bacille Calmette-Guérin.

J S Fok, R S Ho, P K Arora, G E Harding, D W Smith.   

Abstract

The influence of bacille Calmette-Guérin (BCG) on the pathogenesis of experimental airborne tuberculosis was studied. In a model that approximates the conditions under which man is vaccinated and infected, BCG-vaccinated and unvaccinated guinea pigs were infected by the respiratory route with an inoculum that resulted in the inhalation and retention (by each animal) of approximately three virulent tubercle bacilli (Mycobacterium tuberculosis strain H37Rv). Hematogenous seeding of the lungs occurred in unvaccinated animals about three weeks after aerosol infection but did not occur in BCG-vaccinated animals. Furthermore, the lungs of BCG-vaccinated animals failed to kill H37Rv that was introduced intravenously; however, evidence of mycobacteriostatic activity was found throughout the lungs. In view of the importance of hematogenous dissemination to the apex of the lungs in the establishment of pulmonary tuberculosis in man, the foregoing observations suggest a means by which vaccination with BCG may confer acquired resistance to tuberculosis.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 812927     DOI: 10.1093/infdis/133.2.137

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  Comparison of in vitro models for the study of Mycobacterium tuberculosis invasion and intracellular replication.

Authors:  P K Mehta; C H King; E H White; J J Murtagh; F D Quinn
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

2.  Animal model of human disease. Pulmonary tuberculosis. Animal model: Experimental airborne tuberculosis in the guinea pig.

Authors:  D W Smith; G E Harding
Journal:  Am J Pathol       Date:  1977-10       Impact factor: 4.307

3.  Vaccination of guinea pigs with DNA encoding the mycobacterial antigen MPB83 influences pulmonary pathology but not hematogenous spread following aerogenic infection with Mycobacterium bovis.

Authors:  Mark A Chambers; Ann Williams; Graham Hatch; Dolores Gavier-Widén; Graham Hall; Kris Huygen; Douglas Lowrie; Philip D Marsh; R Glyn Hewinson
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

4.  Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis.

Authors:  M A Horwitz; B W Lee; B J Dillon; G Harth
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

5.  The detection of airborne transmission of tuberculosis from HIV-infected patients, using an in vivo air sampling model.

Authors:  A Roderick Escombe; Clarissa Oeser; Robert H Gilman; Marcos Navincopa; Eduardo Ticona; Carlos Martínez; Luz Caviedes; Patricia Sheen; Armando Gonzalez; Catherine Noakes; David A J Moore; Jon S Friedland; Carlton A Evans
Journal:  Clin Infect Dis       Date:  2007-04-09       Impact factor: 9.079

Review 6.  Mycobacterial disease, immunosuppression, and acquired immunodeficiency syndrome.

Authors:  F M Collins
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

Review 7.  What animal models teach humans about tuberculosis.

Authors:  Ashwin S Dharmadhikari; Edward A Nardell
Journal:  Am J Respir Cell Mol Biol       Date:  2008-06-12       Impact factor: 6.914

8.  Mycobacterium bovis BCG vaccine fails to protect protein-deficient guinea pigs against respiratory challenge with virulent Mycobacterium tuberculosis.

Authors:  D N McMurray; M A Carlomagno; C L Mintzer; C L Tetzlaff
Journal:  Infect Immun       Date:  1985-11       Impact factor: 3.441

9.  I-A restricted activation by T cell lines of anti-tuberculosis activity in murine macrophages.

Authors:  G A Rook; B R Champion; J Steele; A M Varey; J L Stanford
Journal:  Clin Exp Immunol       Date:  1985-02       Impact factor: 4.330

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.